- Conditions
- Recurrent Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Interventions
- Montanide ISA 51 VG, MART-1 antigen, laboratory biomarker analysis, Gag:267-274 peptide vaccine, resiquimod
- Drug · Biological · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2401–2424
of 48,567
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
- Interventions
- Metformin, Placebo
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 13 Years to 25 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- ADT+Docetaxel+Enzalutamide
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Hyperkalemia, Chronic Kidney Disease Requiring Chronic Dialysis
- Interventions
- Kalemic Response to Orange Juice, Kalemic Response to Orange Juice with Fiber
- Diagnostic Test · Dietary Supplement
- Lead sponsor
- University of Nevada, Reno
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Reno, Nevada
- Conditions
- Urinary Bladder, Overactive, Incontinence, Urge, Incontinence, Urinary, Urinary Urge Incontinence, Urinary Frequency More Than Once at Night, Nocturia
- Interventions
- OnabotulinumtoxinA 100 UNT
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida
- Conditions
- Metastatic Breast Cancer, HER2-positive Breast Cancer
- Interventions
- BDC-1001, Pertuzumab
- Drug
- Lead sponsor
- Bolt Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Irvine, California • New York, New York • Arlington, Virginia
- Conditions
- Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Extreme Prematurity, Ventilator Lung; Newborn, Ventilation Perfusion Mismatch
- Interventions
- Increase in the PEEP followed by decrease in the PEEP, Decrease in the PEEP followed by increase in the PEEP
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 7 Days to 30 Days
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- AL Amyloidosis
- Interventions
- CAEL-101, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
- Drug · Other
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Scottsdale, Arizona • Duarte, California • Palo Alto, California + 26 more
- Conditions
- Prostate Cancer
- Interventions
- PSMA ADC
- Drug
- Lead sponsor
- Progenics Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • New Orleans, Louisiana • Baltimore, Maryland + 3 more
- Conditions
- Gut Health, Bloating, Irregular Bowel Movements, Gastrointestinal Symptoms
- Interventions
- Active Supplement, Placebo Comparator
- Dietary Supplement
- Lead sponsor
- Belli Welli Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Physical Activity, Patient Engagement
- Interventions
- Text Based Behavioral Intervention for Physical Activity
- Behavioral
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 8 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Glioma
- Interventions
- ABY-029
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Emergency Service, Hospital
- Interventions
- Automated interactive messages, Live outreach
- Behavioral
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Danville, Pennsylvania
- Conditions
- Insulin Sensitivity
- Interventions
- Maltodextrin, Synbiotic, Sevelamer
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Maitake
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Siltuximab, Placebo, Best supportive care (BSC)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Healthy Subjects
- Interventions
- Ziresovir, Placebo
- Drug · Other
- Lead sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey
- Conditions
- Overdose
- Interventions
- Brief youth overdose prevention education, Usual standard of care
- Behavioral · Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Concussion
- Interventions
- Stepped Care
- Behavioral
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 11 Years to 18 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Obesity, Obesity, Morbid, Obesity Associated Disorder, Bariatric Surgery Candidate, Fistula, Gastric, Roux-en-y Anastomosis Site, Ulcer, Gastric, Abdominal Pain, Abdominal Obesity, Complication of Surgical Procedure, Complication of Treatment, Complication,Postoperative, Weight Gain, Weight Loss, Leak, Anastomotic, Delayed Gastric Emptying Following Procedure
- Interventions
- Primary Obesity Endoscopic Procedures, Endoscopic Revision of Bariatric Surgical Procedures, Bariatric Surgery Procedures, Endoscopic Sleeve Gastroplasty, Trans-oral Outlet Reduction, Intragastric Balloon, Primary obesity surgery endoluminal, Restorative obesity surgery endoluminal, Argon Plasma Coagulation, Gastroplasty with Endoscopic Myotomy, Bariatric Endoscopic Antral Myotomy, Pylorus Sparing Antral Myotomy, Aspiration Therapy
- Procedure · Device
- Lead sponsor
- Christopher C. Thompson, MD, MSc
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Follicular Lymphoma
- Interventions
- VELCADE, Bendamustine, Rituximab
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Bismarck, North Dakota
- Conditions
- Healthy
- Interventions
- JNJ-42847922 10 milligram (mg), JNJ-42847922 20 mg, JNJ-42847922 40 mg, JNJ-42847922 60 or 80 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Cypress, California • Knoxville, Tennessee
- Conditions
- Breast Carcinoma
- Interventions
- Decision Aid, Discussion, Questionnaire Administration
- Other · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- RP-3500, Olaparib
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah